logo
PricingOpen Demat Account at ₹0 AMCBecome a PartnerCustomer ServiceDhan SupportDhan Blog
fuzz
Logo
MadeForTrade CommunityIndicator by Dhan
Home
InvestmentsIPOSahajanand Medical Technologies IPO

Sahajanand Medical Technologies IPO

Mainboard

Open Date

15 Oct 2026

Close Date

19 Oct 2026

Min Investment

₹ 14,061

Lot Size

43

Issue Size

₹ 475.48 Cr

Price Range

₹ 327 - ₹ 344

Subscribed

0.03 x
Apply Now
status

IPO Open Now.

IPO Timeline
check
IPO Offer Start
15 Oct 2026
check
IPO Offer Ends
19 Oct 2026
check
Allotment Finalisation
21 Oct 2026
check
Refund Initialisation
22 Oct 2026
check
Non-Institutional Buyers (sHNI)
22 Oct 2026
check
Listing of Shares
23 Oct 2026
IPO Subscription Details as on 15 Oct 2026, 10:42 AM
Qualified Instituational Buyers (QiB)
0 x
Retail
0.06 x
Employees
0.01 x
Total
0.03 x
Non-Institutional Buyer (bHNI)
0.01 x
Non-Institutional Buyer (sHNI)
0.04 x
Note: This information is provided for general guidance only. Dates may be subject to change.
border
About the Company
Sahajanand Medical Technologies (SMT), founded in 2001, is a Class III and Class C/D medical devices company specializing in technologically advanced cardiovascular devices across Vascular Intervention (VI) and Structural Heart (SH) segments. The company's portfolio includes Drug-Eluting Stents (DES), PTCA balloons, Coronary DCBs, TAVI systems, and Occluders, marketed across 77 countries in Fiscal 2026. The company holds a ~25% market share in India's DES segment and ranks among the top five in Germany, Spain, Poland, and Brazil by DES sales volume. With three manufacturing facilities in India and Thailand, 119 granted patents, and R&D spend of ~8-9% of revenue, SMT is recognized as an R&D-driven, globally diversified medtech company.
rocket

Founded In

2001

rocket

Director

Jose Calle Gordo

Financials of Sahajanand Medical Technologies IPO

Income Statement
Balance Sheet
Cash Flows
Total Income
Total Expenses
Total Profit
Key Performance IndicatorsMar 2024Mar 2025Mar 2026
Operating Revenue901.601,024.881,210.50
Other Income6.9911.088.22
Total Income
908.591,035.961,218.73
Total Expenses
875.50980.121,138.43
Profit Before Tax33.0940.8180.29
Total Profit
-7.3525.1569.08

All figures are in crores (₹)

border

Utilisation of Proceeds

All figures are in crores (₹)

PurposeAmount
The Offer involves the sale of Equity Shares by the Selling Shareholders, constituting a specified percentage of the pre-Offer Equity Share capital of the Company. The Company will not receive any proceeds from the Offer, as all proceeds will be received by the Selling Shareholders after deduction of their respective portion of Offer-related expenses and relevant taxes.-
The Company aims to achieve the benefits of listing its Equity Shares on the Stock Exchanges to enhance its visibility and brand, provide liquidity to existing Shareholders, and create a public market for the Equity Shares in India.-
The total expenses of the Offer are estimated at a specified amount in millions. These expenses are to be shared among the Selling Shareholders in proportion to the number of Equity Shares sold, covering fees for BRLMs, registrar, legal counsel, advertising, and other regulatory costs.-
border
  • Technologically Advanced Products in High Barrier Segments: The company holds a comprehensive portfolio of advanced cardiovascular implants including DES, Drug-coated balloons, PTCA balloons, TAVI systems, and Occluders, supported by strong clinical evidence and compliant with stringent domestic and international regulatory standards.
  • Flagship DES – Supraflex Cruz with Superior Deliverability: The company's flagship DES, Supraflex Cruz, is positioned as the 'most deliverable' stent in its class per the F&S Report, with 28,383 clinical trial participants globally and results published in top-tier journals such as The Lancet (impact factor 109) and NEJM (impact factor 84.5).
  • Proven Research and Development Capabilities: The company operates two R&D centers (India and Thailand) with 156 professionals, holding 119 patents granted globally, 78 patent applications in the pipeline, and R&D expenses of ₹1,041.64 million (8.61% of revenue) in Fiscal 2026.
  • World-First Innovation in Biodegradable Polymer DES: The company was the first in the world to receive CE certification for a biodegradable polymer-based paclitaxel-eluting stent (Infinnium) in December 2005, and further developed the proprietary LDZ link enhancing deliverability of Supraflex Cruz, per the F&S Report.
  • Leadership in India and Key International DES Markets: The company holds nearly 25% market share in India's DES sales volume in Fiscal 2026 and is among the top five companies by DES sales volume in Germany, Spain, Poland, and Brazil, and top five in Occluder sales in Thailand, South Korea, and India, as of March 31, 2026.
  • Deep Global Sales and Marketing Presence: The company marketed products in 77 countries in Fiscal 2026, with international revenue growing at a CAGR of 23.34% from ₹5,878.44 million (Fiscal 2024) to ₹8,942.01 million (Fiscal 2026), operating across 6 direct, 20 hybrid, and 39 distributor-led markets.
  • Diversified, Integrated, and Efficient Manufacturing Facilities: The company operates three integrated manufacturing facilities in Surat, Hyderabad (India), and Nonthaburi (Thailand), accredited by CE, ANVISA, TGA Australia, Korean GMP, and Health Canada, with ~33% of Hyderabad's available area currently utilized, allowing scalable expansion.
  • Proven M&A and Strategic Collaborations Playbook: The company has successfully completed four acquisitions in seven years, including Vascular Concepts, Vascular Innovations, Imex (Spain), and Zarek (Brazil), achieving a combined CAGR of 34.32% from Imex and Zarek since Fiscal 2020, and expanding SH revenue to ₹2,030.62 million in Fiscal 2026.
  • Experienced Leadership Team Backed by Reputed Institutional Investors: The company's senior leadership team of 11 members (KMPs and SMPs) averages 26 years of industry experience and 8 years of tenure, supported by investors including Samara Capital Markets Holding Limited, Kotak Pre-IPO Opportunities Fund, Plutus Wealth Management LLP, and Ashish Kacholia.

Open IPOs for Subscription

No Open IPOs

Stay tuned, there will be more IPOs listing soon!


fuzz

Listed IPOs

No Listed IPOs

Stay tuned, there will be more IPOs listing soon!


Invest & Trade with a Trading
Platform That's #MadeForTrade

Open your Dhan Account in minutes!
border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com›store›apps›sebiscores iOS: https://apps.apple.com›app›sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

SEBI presents Samajh Se Investing Simple:

  • Understand Before You Invest
  • Choose Regulated Investment Products
  • Start Early, Stay Invested
  • Beware of Investment Frauds

Reporting of Short Sell Transactions by Clients:

Clients must report any short sale transaction, by emailing help@dhan.co with the subject “Reporting of Short Sell” on the same day.


Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution